These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35767614)

  • 1. In vivo multidimensional CRISPR screens identify
    Ji P; Gong Y; Jin ML; Wu HL; Guo LW; Pei YC; Chai WJ; Jiang YZ; Liu Y; Ma XY; Di GH; Hu X; Shao ZM
    Sci Adv; 2022 Jul; 8(26):eabl8247. PubMed ID: 35767614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo CRISPR screens identify
    Feng X; Yang C; Huang Y; Su D; Wang C; Wilson LL; Yin L; Tang M; Li S; Chen Z; Zhu D; Wang S; Zhang S; Zhang J; Zhang H; Nie L; Huang M; Park JI; Hart T; Jiang D; Jiang K; Chen J
    Proc Natl Acad Sci U S A; 2024 Sep; 121(39):e2406325121. PubMed ID: 39298484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo CRISPR screens identify the E3 ligase Cop1 as a modulator of macrophage infiltration and cancer immunotherapy target.
    Wang X; Tokheim C; Gu SS; Wang B; Tang Q; Li Y; Traugh N; Zeng Z; Zhang Y; Li Z; Zhang B; Fu J; Xiao T; Li W; Meyer CA; Chu J; Jiang P; Cejas P; Lim K; Long H; Brown M; Liu XS
    Cell; 2021 Oct; 184(21):5357-5374.e22. PubMed ID: 34582788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational Discovery of Cancer Immunotherapy Targets by Intercellular CRISPR Screens.
    Yim S; Hwang W; Han N; Lee D
    Front Immunol; 2022; 13():884561. PubMed ID: 35651625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deciphering the role of LGALS2: insights into tertiary lymphoid structure-associated dendritic cell activation and immunotherapeutic potential in breast cancer patients.
    Li S; Zhang N; Zhang H; Yang Z; Cheng Q; Wei K; Zhou M; Huang C
    Mol Cancer; 2024 Sep; 23(1):216. PubMed ID: 39350165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo CRISPR screens identify RhoV as a pro-metastasis factor of triple-negative breast cancer.
    Jin ML; Gong Y; Ji P; Hu X; Shao ZM
    Cancer Sci; 2023 Jun; 114(6):2375-2385. PubMed ID: 36898847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
    Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
    Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of cabazitaxel on macrophages improves CD47-targeted immunotherapy for triple-negative breast cancer.
    Cao X; Li B; Chen J; Dang J; Chen S; Gunes EG; Xu B; Tian L; Muend S; Raoof M; Querfeld C; Yu J; Rosen ST; Wang Y; Feng M
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33753567
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypoxia induces HIF1α-dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy.
    Ma S; Zhao Y; Lee WC; Ong LT; Lee PL; Jiang Z; Oguz G; Niu Z; Liu M; Goh JY; Wang W; Bustos MA; Ehmsen S; Ramasamy A; Hoon DSB; Ditzel HJ; Tan EY; Chen Q; Yu Q
    Nat Commun; 2022 Jul; 13(1):4118. PubMed ID: 35840558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MUC1-C integrates activation of the IFN-γ pathway with suppression of the tumor immune microenvironment in triple-negative breast cancer.
    Yamashita N; Long M; Fushimi A; Yamamoto M; Hata T; Hagiwara M; Bhattacharya A; Hu Q; Wong KK; Liu S; Kufe D
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33495298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach.
    Bareche Y; Buisseret L; Gruosso T; Girard E; Venet D; Dupont F; Desmedt C; Larsimont D; Park M; Rothé F; Stagg J; Sotiriou C
    J Natl Cancer Inst; 2020 Jul; 112(7):708-719. PubMed ID: 31665482
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells.
    Dong MB; Wang G; Chow RD; Ye L; Zhu L; Dai X; Park JJ; Kim HR; Errami Y; Guzman CD; Zhou X; Chen KY; Renauer PA; Du Y; Shen J; Lam SZ; Zhou JJ; Lannin DR; Herbst RS; Chen S
    Cell; 2019 Aug; 178(5):1189-1204.e23. PubMed ID: 31442407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of inflammatory infiltrates in triple negative breast cancer.
    Matsumoto H; Koo SL; Dent R; Tan PH; Iqbal J
    J Clin Pathol; 2015 Jul; 68(7):506-10. PubMed ID: 25750267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adipogenesis in triple-negative breast cancer is associated with unfavorable tumor immune microenvironment and with worse survival.
    Oshi M; Tokumaru Y; Angarita FA; Lee L; Yan L; Matsuyama R; Endo I; Takabe K
    Sci Rep; 2021 Jun; 11(1):12541. PubMed ID: 34131208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MYC suppresses STING-dependent innate immunity by transcriptionally upregulating DNMT1 in triple-negative breast cancer.
    Wu SY; Xiao Y; Wei JL; Xu XE; Jin X; Hu X; Li DQ; Jiang YZ; Shao ZM
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34321275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo genome-wide CRISPR screen reveals breast cancer vulnerabilities and synergistic mTOR/Hippo targeted combination therapy.
    Dai M; Yan G; Wang N; Daliah G; Edick AM; Poulet S; Boudreault J; Ali S; Burgos SA; Lebrun JJ
    Nat Commun; 2021 May; 12(1):3055. PubMed ID: 34031411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Taraxacum mongolicum extract inhibited malignant phenotype of triple-negative breast cancer cells in tumor-associated macrophages microenvironment through suppressing IL-10 / STAT3 / PD-L1 signaling pathways.
    Deng XX; Jiao YN; Hao HF; Xue D; Bai CC; Han SY
    J Ethnopharmacol; 2021 Jun; 274():113978. PubMed ID: 33716082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer.
    Xiao Y; Ma D; Zhao S; Suo C; Shi J; Xue MZ; Ruan M; Wang H; Zhao J; Li Q; Wang P; Shi L; Yang WT; Huang W; Hu X; Yu KD; Huang S; Bertucci F; Jiang YZ; Shao ZM;
    Clin Cancer Res; 2019 Aug; 25(16):5002-5014. PubMed ID: 30837276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of metabolic reprogramming in immune escape of triple-negative breast cancer.
    Bao R; Qu H; Li B; Cheng K; Miao Y; Wang J
    Front Immunol; 2024; 15():1424237. PubMed ID: 39192979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single peptides and combination modalities for triple negative breast cancer.
    Razazan A; Behravan J
    J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.